Celesio suffers fall in revenue and earnings
This article was originally published in Scrip
Celesio's revenue fell by 2.3% to €21.8 billion and EBITDA dropped by 22% to €657.3 million in 2008, the company has announced.
You may also be interested in...
"Unscrupulous traders" are likely to begin selling Tamiflu (oseltamivir) and Relenza (zanamivir) counterfeits if the swine flu situation escalates, the Royal Pharmaceutical Society of Great Britain (RPSBG) has warned. The alert comes in a letter to pharmacists providing information on the swine flu outbreak.
The Innovative Medicines Initiative Joint Undertaking (IMI JU) has agreed to fund the PROTECT project (Pharmacoepidemiological Research on Outcomes of Therapeutics by a European ConsorTium).
Johnson & Johnson has reclaimed the top spot in the 10th Annual Harris Interactive Quotient Study, marking it as having the best reputation of the 60 most visible companies in the US.